Imraldi, an investigative biosimilar product to Humira (adalimumab), received a positive review from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) as a potential treatment for ankylosing spondylitis and other conditions. This favorable opinion may help Samsung Bioepis (a venture created…
Patients with ankylosing spondylitis (AS) who smoke are twice as likely to have cumulative spinal structural damage, according to preliminary results of a systematic review study conducted by researchers at the Izmir Katip Celebi University, Turkey. This finding was the subject of an oral presentation titled “The…
Novartis recently announced that its leading drug Cosentyx (secukinumab) improves both signs and symptoms of active ankylosing spondylitis (AS), according to the results of a three-year Phase 3 extension trial called MEASURE 1. The findings were presented recently at the Annual European Congress of Rheumatology (EULAR 2017) in Madrid, Spain.
Get regular updates to your inbox.